Recent Analysts’ Ratings Updates for Amicus Therapeutics (FOLD)

Amicus Therapeutics (NASDAQ: FOLD) has recently received a number of price target changes and ratings updates:

• 12/17/2025 – Amicus Therapeutics is now covered by analysts at Citigroup Inc.. They set a “buy” rating and a $17.00 price target on the stock.
• 12/15/2025 – Amicus Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Amicus Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – Amicus Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – Amicus Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – Amicus Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/13/2025 – Amicus Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/8/2025 – Amicus Therapeutics was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 11/6/2025 – Amicus Therapeutics had its price target raised by analysts at JPMorgan Chase & Co. from $18.00 to $19.00. They now have an “overweight” rating on the stock.
• 11/5/2025 – Amicus Therapeutics had its price target raised by analysts at The Goldman Sachs Group, Inc. from $9.00 to $11.00. They now have a “neutral” rating on the stock.
• 10/26/2025 – Amicus Therapeutics was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.

Insider Transactions at Amicus Therapeutics

In other Amicus Therapeutics news, insider David Michael Clark sold 25,643 shares of the business’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $11.00, for a total transaction of $282,073.00. Following the completion of the sale, the insider owned 271,332 shares in the company, valued at approximately $2,984,652. The trade was a 8.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Jeff Castelli sold 76,158 shares of the company’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $10.16, for a total transaction of $773,765.28. Following the transaction, the insider owned 439,318 shares in the company, valued at approximately $4,463,470.88. The trade was a 14.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 319,808 shares of company stock valued at $3,293,653 over the last ninety days. Company insiders own 2.20% of the company’s stock.

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.